RxDoctor Payments Data

Robert Sommer, MD

Adult Congenital Heart Disease · New York, NYNPI 1316954514

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (52.6%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. W. L. Gore & Associates, Inc. accounts for 82.3% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2022 at $31,172 and has fallen 75.0% since, to $7,797 in 2025.

$82,171in general payments, 2019–2025

Across 98 payments — averaging $838.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • W. L. Gore & Associates, Inc.$68K
  • Abbott$8K
  • Boston Scientific$5K
  • Biosense Webster, Inc.$1K
  • Boehringer Ingelheim$114
  • Pfizer$38
  • plus $59 from 3 others
$892,515in research payments, 2019–2025

Across 154 payments — averaging $5795.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • W. L. Gore & Associates, Inc.$518K
  • Abbott$136K
  • Edwards Lifesciences$121K
  • Boston Scientific$108K
  • Biosense Webster, Inc.$9K

What the payments were for

  • Consulting fees$43,21353%
  • Speaking & faculty fees$30,08537%
  • Travel & lodging$4,7146%
  • Food & beverage$4,1605%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few adult congenital heart disease providers in New Yorkto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$113,454
Medicare patients
142
Services billed
370

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other adult congenital heart disease in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →